Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Monoclonal Antibodies
"Selection of Monoclonal Antibody E48 IgG or U36 IgG for Adjuvant Radioimmunotherapy in Head and Neck Cancer Patients."
May 26th, 1997
According to the authors' abstract of an article published in British Journal of Cancer, "Preliminary data from recent clinical radioimmunoscintigraphy studies indicate that Tc-99m-labelled murine monoclonal antibodies (MAbs) E48 and U36 have a similar ability to target squamous cell carcinoma of the head and neck (HNSCC) selectively. In the present study we describe additional aspects of murine and chimeric MAb (mMAb and cMAb) E48 and U36, which might influence the selection of one MAb for adjuvant radioimmunotherapy. To make direct comparison possible, ten patients received 11.2 ± 0.3 and 11.1 ± 0.2 mg (n = 5) or 51.1 ± 0.1 and 51.0 ± 0.4 mg (n = 5) of both...
Source: Cancer Weekly (1997-05-26)
|
|
Advertisement |
|
|
